ClinicalTrials.gg
Enrolling by invitationNCT07918027Updated Nov 5, 2026

Reducing Blood Loss During Myomectomy by Comparing Local Epinephrine and Uterine Artery Tourniquet During Procedure

An interventional study of Temporary uterine artery occlusion using a Foley catheter tourniquet during myomectomy and Local infiltration of dilute epinephrine into the myoma bed and surrounding myometrium during myomectomy. in Local Epinephrine in Myomectomy, sponsored by Pakistan Institute of Medical Sciences. Enrolling by invitation at 1 site in Pakistan. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pakistan Institute of Medical Sciences · Not applicable, Interventional, and Other

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

To reduce blood loss during myomectomy We will make 2 groups and will compare the use of epinephrine and uterine artery tourniquet in each group Blood loss will be calculated and quantified then each group will be analyzed accordingly

02

Conditions studied

  • Local Epinephrine in Myomectomy
03

In context

Lead sponsor

Pakistan Institute of Medical Sciences is the lead sponsor of 55 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 10 Women 18 to 50 yrs

Exclusion criteria

Exclusion Criteria:

  • known bleeding disorder Pregnancy Hepatic or renal impairment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Arm A: Uterine Artery Tourniquet Group -

    Myomectomy performed using temporary uterine artery occlusion with folley catheter

    Other: Temporary uterine artery occlusion using a Foley catheter tourniquet during myomectomy

  • Active comparator
    Arm B: Epinephrine Infiltration Group

    Myomectomy performed using local epinephrine infiltration (1:250,000) into the myoma bed to reduce blood loss.

    Other: Local infiltration of dilute epinephrine into the myoma bed and surrounding myometrium during myomectomy.

Interventions

  • OtherTemporary uterine artery occlusion using a Foley catheter tourniquet during myomectomy

    Blood loss comparison in myomectomy

  • OtherLocal infiltration of dilute epinephrine into the myoma bed and surrounding myometrium during myomectomy.

    Blood loss comparison in myomectomy

06

What researchers measure

Primary outcomes

  1. Blood Loss

    Blood loss in term of millilitres By measuring suction and soaked gauzes will be calculated and added together

    Time frame: 6 months

  2. Operative Time

    Total surgery time in terms of hours and minutes will be calculated

    Time frame: Intraoperative

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 5, 2026
StartEst.
Feb 2027
Primary completionEst.
Jul 2027
CompletionEst.
Aug 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07918027
Lead sponsor
Pakistan Institute of Medical Sciences
Responsible party
Saira Tariq (Resident, Pakistan Institute of Medical Sciences) — Principal investigator
First posted
Nov 5, 2026
Start date
Feb 2027 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion